Form 8-K - Current report:
SEC Accession No. 0000875045-25-000014
Filing Date
2025-05-01
Accepted
2025-05-01 06:52:09
Documents
15
Period of Report
2025-05-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K biib-20250501.htm   iXBRL 8-K 24074
2 EX-99.1 exhibit991-q12025pressrele.htm EX-99.1 396432
6 newbiogenlogoa.jpg GRAPHIC 2811
  Complete submission text file 0000875045-25-000014.txt   581833

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT biib-20250501.xsd EX-101.SCH 1804
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT biib-20250501_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT biib-20250501_pre.xml EX-101.PRE 12526
17 EXTRACTED XBRL INSTANCE DOCUMENT biib-20250501_htm.xml XML 2692
Mailing Address 225 BINNEY STREET CAMBRIDGE MA 02142
Business Address 225 BINNEY STREET CAMBRIDGE MA 02142 7814642000
BIOGEN INC. (Filer) CIK: 0000875045 (see all company filings)

EIN.: 330112644 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-19311 | Film No.: 25899307
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)